Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, 4301 W. Markham Street, Slot 511, Little Rock, AR 72205-7194, USA.
Infect Immun. 2011 Mar;79(3):986-96. doi: 10.1128/IAI.00881-10. Epub 2010 Nov 15.
Chlamydia trachomatis genital infection is a worldwide public health problem, and considerable effort has been expended on developing an efficacious vaccine. The murine model of C. muridarum genital infection has been extremely useful for identification of protective immune responses and in vaccine development. Although a number of immunogenic antigens have been assessed for their ability to induce protection, the majority of studies have utilized the whole organism, the major outer membrane protein (MOMP), or the chlamydial protease-like activity factor (CPAF). These antigens, alone and in combination with a variety of immunostimulatory adjuvants, have induced various levels of protection against infectious challenge, ranging from minimal to nearly sterilizing immunity. Understanding of the mechanisms of natural infection-based immunity and advances in adjuvant biology have resulted in studies that are increasingly successful, but a vaccine licensed for use in humans has not yet been brought to fruition. Here we review immunity to chlamydial genital infection and vaccine development using the C. muridarum model.
沙眼衣原体生殖器感染是一个全球性的公共卫生问题，人们付出了大量努力来开发有效的疫苗。鼠型沙眼衣原体生殖器感染模型对于鉴定保护性免疫反应和疫苗开发非常有用。尽管已经评估了许多免疫原性抗原诱导保护的能力，但大多数研究都使用了整个生物体、主要外膜蛋白（MOMP）或衣原体蛋白酶样活性因子（CPAF）。这些抗原单独使用或与各种免疫刺激性佐剂联合使用，在对抗感染的挑战方面产生了不同程度的保护作用，从最小到几乎完全的免疫。对基于自然感染的免疫机制的理解以及佐剂生物学的进步，使得研究越来越成功，但尚未开发出可用于人类的疫苗。在这里，我们使用鼠型沙眼衣原体模型综述了针对沙眼衣原体生殖器感染的免疫和疫苗开发。
